Yahoo
Home
AUTO_INSURANCE_QUOTES_EDMONTON
Oops, something went wrong
Skip to navigation
Skip to main content
Skip to right column
Home
News
Finance
Sports
More
News
US
Politics
World
Tech
Science
Originals
2026 Elections
Weather
Newsletters
Finance
My portfolio
News
Markets
Research
Community
Personal finance
Videos
Sports
Fantasy Football 2026
NFL
College football
NBA
MLB
NHL
College basketball
Soccer
Fantasy
Sports Betting
NFL Odds
Yahoo Sports AM
Shopping
Style
Beauty
Health
Home and garden
Tech
Gift ideas
Stores
Shopping guides
Deals
Toys and games
Shopping lists
General
Entertainment
Celebrity
TV
Movies
Music
How to Watch
Videos
Nonfiction Hotlist
Games
Life
Health
Parenting
Pets
Horoscopes
Food
Travel
Autos
Local
Selected edition
US
English
Sign in
My Portfolio
Watchlists
Portfolios
Markets
Stocks
Most Active
Day Gainers
Day Losers
Trending
Highest Dividend
Large Cap
Small Cap
Most Expensive
Highest Beta
Pink Sheet
Unusual Volume
Crypto
Most Active
Day Gainers
Day Losers
Private Companies
52 Week Gainers
Recently Funded
Most Funded
Options
Day Gainers
Day Losers
Highest Open Interest
Highest Implied Volatility
Sectors
Technology
Financial Services
Consumer Cyclical
Consumer Defensive
Communication Services
Healthcare
Industrials
Treasury Bonds
Currencies
World Indices
Commodities
ETFs
Mutual Funds
News
Markets
Stock Market News
Real Estate
Magnificent 7
Private Markets
Futures & Derivatives
Originals
Premium News
Newsletters
Economy & Policy
Earnings
Oil & Gas
Strait of Hormuz
Tariffs
Clean Energy
Tech
Aerospace & Defense
Enterprise Cloud
Exchange-Traded Funds
Research & Tools
Calendars
Earnings Calendar
IPO Calendar
Stock Splits
Economic Events
Screeners
Equities
Most Shorted
Most Active Penny Stocks
Analyst Strong Buy
Stock Comparison
Currency Converter
Advanced Charts
Community
Premium Research
AlphaSpace
Stock Picks
Investment Ideas
Research Reports
Personal Finance
My Money
BETA
Credit Cards
Compare Credit Cards
Best 0% APR Cards
Best Balance Transfer
Best Cash Back Cards
Best Travel Cards
Banking
CD Rates
Best High-Yield Savings
Best Money Market
Best Free Checking
Best Online Banks
Mortgage
Best Mortgage Lenders
Best Mortgage Rates
Mortgage Refinance
Mortgage Calculator
Mortgage Affordability Calculator
Student Loans
Federal vs. Private
FAFSA Guide
Student Loan Assistance
Student Loan Forgiveness
Paying Off Student Loans
Personal Loans
Best Personal Loans
Get Approved
Best Lenders
Insurance
Find Car Insurance
Types of Car Insurance
Car Insurance Discounts
Find Life Insurance
Taxes
How to File
Refund Status
Tax Extension
Child Tax Credit
Investing
Investing Basics
Real Estate Investing
Retirement Basics
Calculators
Watch
Daily Shows
The 8:30
Sozzi Unleashed
The Daily Wolf
Market Hang
In the Loop
Weekly Shows
Built Different
How They Run
Power Players
The Big Idea
Trader Talk
ETF Report
FA Corner
More to Watch
Must-watch Interviews
Mag 7
Fed Watch
Crypto
AI
Network
AlphaSpace
Get Finance Plus
NasdaqCM - Delayed Quote
•
USD
Pasithea Therapeutics Corp. (KTTAW)
0.0028
+0.0028
(0.00%)
At close: September 15 at 2:22:57 PM EDT
Comparisons
Indicators
Technicals
Corporate events
Draw
Loading Chart for KTTAW
Select
Chart Range Bar
1D
5D
1M
3M
6M
YTD
1Y
5Y
All
Interval:
1 min
In partnership with ChartIQ
Recent News
Pasithea Therapeutics Announces Presentation of PAS-004 Data to European Society for Medical Oncology (ESMO) Congress 2026
New Strong Buy Stocks for July 20th
Pasithea Therapeutics Announces Exhibit at Children’s Tumor Foundation 2026 NF Conference
Pasithea Therapeutics Announces Grant of Rare Pediatric Disease Designation (RPDD) by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1)
Pasithea Therapeutics to Host Virtual KOL Event on NF1 Treatment November 4, 2026
Pasithea Therapeutics Announces Positive PAS-004 Clinical Data from Phase 1 Advanced Cancer Study Presented at ESMO Congress 2026
Pasithea Therapeutics Announces Presentation of Initial PAS-004 Clinical Data from Ongoing Phase 1/1b Clinical Trial in Adult NF1 Patients at the 2026 European Neurofibromatosis Conference
Pasithea Therapeutics Announces Participation in B. Riley Securities Mind, Muscle & Vision Summit
Pasithea Therapeutics Announces Positive Interim Phase 1 Advanced Cancer Study Data Demonstrating Long-Term Safety and Tolerability, and Durable Clinical Activity in MEK/BRAF-Pretreated Patients, plus Protocol Expansion
Pasithea Therapeutics Announces Amendments to Clinical Study Protocol for Phase 1/1B NF1 Clinical Trial
Pasithea Therapeutics (KTTA) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
Related Tickers
Mobilize
your Website
View Site in Mobile
|
Classic
Share by:
